Literature DB >> 16155015

Novel immune-based treatment strategies for chronic lymphocytic leukemia.

William G Wierda1, Thomas J Kipps, Michael J Keating.   

Abstract

Immune-based treatments represent a new group of therapeutic strategies for patients with cancer, including chronic lymphocytic leukemia (CLL), that employ immune effector mechanisms. Among these strategies is passive immunotherapy with monoclonal antibody, alone or in combination with chemotherapy. Active immunotherapy strategies currently under development include vaccines, administration of expanded and activated T cells, and allogeneic stem cell transplantation. These immune-based strategies represent new treatments with potentially complementary mechanisms of action to standard therapies and signify major advances in treatments for patients with CLL.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16155015     DOI： 10.1200/JCO.2005.05.008

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  14 in total

1.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Authors:  Xueqing Liang; E Ashley Moseman; Michael A Farrar; Veronika Bachanova; Daniel J Weisdorf; Bruce R Blazar; Wei Chen
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

2.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

Review 3.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

5.  Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

Authors:  Steven P Treon; Jacob D Soumerai; Zachary R Hunter; Christopher J Patterson; Leukothea Ioakimidis; Brad Kahl; Michael Boxer
Journal:  Blood       Date:  2011-05-12       Impact factor: 22.113

6.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

Review 7.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Michael J Keating; Jennifer R Brown; John G Gribben; Mary Browning; Laura Z Rassenti; Andrew W Greaves; Donna Neuberg; Susan M O'Brien
Journal:  Cancer       Date:  2010-08-30       Impact factor: 6.860

Review 9.  New agents in chronic lymphocytic leukemia.

Authors:  Tadeusz Robak
Journal:  Curr Treat Options Oncol       Date:  2006-05

10.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.